The M injection for weight loss: tirzepatide explained

How does the M injection actually work inside the body?

Most weight-loss injections target a single gut hormone called GLP-1, which signals fullness to the brain and slows the rate at which your stomach empties. Tirzepatide does that too, but it also activates a second receptor (GIP) that plays a distinct role in energy regulation and fat storage. This dual action is why many clinicians consider it a step forward from earlier GLP-1 medicines. You can read more about how these pathways interact on our weight-loss injection overview.

In practical terms, most people taking tirzepatide find their appetite falls noticeably during the week. Portion sizes that felt normal before treatment become difficult to finish. Cravings (particularly for high-calorie foods) tend to reduce too. The medicine is given once weekly, via a pre-filled pen injected under the skin of the abdomen, thigh or upper arm, rotating sites each time. Our Mounjaro injection page covers the injection technique in more detail. The NHS's tirzepatide medicines page gives a clear patient-level summary of how tirzepatide works and what to expect.

UK strengths run from 2.5 mg up to 15 mg. The first pen's job is adjustment, your system gets used to the medicine before any therapeutic dose is reached. A prescriber decides when and whether to increase, based on your response and tolerability.

Who is tirzepatide licensed to treat, and does your weight qualify?

The UK licence covers adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition, for example, high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK clinical guidance, specifically a 2.5 kg/m² reduction for South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds. A BMI number alone does not confirm suitability; a prescriber weighs the full picture, including your medical history, other medicines you take and any contraindications.

NICE recommended tirzepatide (TA1026, published December 2024) for NHS use in adults with a BMI of 35 or above plus at least one weight-related comorbidity. Private prescribing follows the licensed criteria, which are somewhat broader. Our eligibility guide walks through exactly what qualifying conditions look like in practice, and the NICE appraisal of tirzepatide (TA1026) sets out the NHS recommendation in full.

Not suitable: anyone under 18, people who are pregnant, breastfeeding or actively trying to conceive, and those with certain conditions including a personal or family history of medullary thyroid carcinoma. If you take an oral contraceptive pill, your prescriber will advise adding a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, as tirzepatide can reduce absorption of oral medicines taken at the same time.

What side effects should you expect from the injection?

The side-effect profile is well characterised after extensive clinical trials. Gastrointestinal symptoms dominate: nausea, vomiting, constipation, loose stools and reflux are the most commonly reported. They tend to cluster in the first day or two after each injection, particularly after starting or moving up a dose step, and for most people they become much less noticeable within a week or so. Eating smaller meals, avoiding very fatty or rich food and staying well hydrated all help.

Less common but worth knowing: some people experience fatigue, headaches or dizziness, particularly early in treatment. Injection-site reactions (mild redness or itching at the pen site) occur occasionally. Rotating the injection site each week reduces that risk. Alcohol swabs are useful for cleaning the site before each injection.

There are symptoms that need prompt medical attention. Severe, persistent abdominal pain that spreads to the back (with or without vomiting) should not be waited out; that pattern can indicate pancreatitis, which the MHRA highlighted in a January 2026 safety communication. Gallbladder symptoms, signs of dehydration from prolonged vomiting or diarrhoea, and any allergic reaction also warrant same-day contact with a clinician. You can report any suspected side effect directly at the MHRA Yellow Card scheme. Our FAQs address the most common questions patients raise once treatment starts.

Is the M injection available on the NHS, and what does private access look like?

NHS access to tirzepatide is rolling out in phases. From June 2025, patients with a BMI of 40 or above and four or more of five specified conditions (high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, type 2 diabetes) became eligible. A second cohort (BMI 35 to 39.9 with four or more of those conditions) opened in June 2026. Further phases follow through 2027. GP practices may now prescribe under the 2026/27 GP contract, but participation varies by practice. In most parts of England, NHS access still means a referral, a wait and strict criteria. Our weight-loss injections page compares NHS and private routes side by side.

Private prescribing through a regulated online pharmacy is the alternative for people who meet the licensed criteria but either do not qualify for the current NHS phase or prefer not to wait. If you are also exploring other injectable options, our guide to weight loss injection r covers how that treatment compares and what to expect from it. The only legal route (NHS or private) is a prescription following a clinical assessment, and if you are wondering where you can buy weight loss injections safely and legally, our dedicated page explains which regulated sources to look for and what to avoid. Any seller offering these injections without a prescription is operating outside the law, and the MHRA has seized tens of millions of fake pens in recent enforcement operations.

If you'd like a prescriber to review whether tirzepatide is right for you, speak to our prescribers through a free consultation, reviewed the same day by a real clinician, not software.